“Any product liability claim brought against us, with or without merit, could result in: • an inability to commercialize, or if commercialized, a decreased demand for, cytisinicline; • if commercialized, product recalls, withdrawals of labeling, marketing or promotional restrictions or the need for product modification; • initiation of investigations by regulators; • withdrawal of clinical trial volunteers, investigators, patients or trial sites or limitations on approved indications; • loss of revenue, if any;”
“Further contributing to the increase in research and development expenses was a $1.4 million increase in personnel-related expenses, driven by stock-based compensation grants to employees and severance payments to certain former employees, and a $1.2 million increase in allocated facility and other expenses primarily related to facility expenses for our Emeryville Lease (defined below) and an increase in non-program specific consulting fees.”
“The increase in interest expense for the three months ended March 31, 2026 as compared to the same period in 2025 was due to a higher average debt balance of $15.0 million in 2026 as compared to $10.0 million in 2025.”